CD34(+)CD19(−)CD22(+) B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies

CD19-directed immunotherapies have revolutionized the treatment of advanced B-cell acute lymphoblastic leukemia (B-ALL). Despite initial impressive rates of complete remission (CR) many patients ultimately relapse. Patients with B-ALL successfully treated with CD19-directed T cells eventually relaps...

Descripción completa

Detalles Bibliográficos
Autores principales: Bueno, Clara, Barrera, Susana, Bataller, Alex, Ortiz-Maldonado, Valentín, Elliot, Natalina, O’Byrne, Sorcha, Wang, Guanlin, Rovira, Montse, Gutierrez-Agüera, Francisco, Trincado, Juan L., González-González, María, Morgades, Mireia, Sorigué, Marc, Bárcena, Paloma, Zanetti, Samanta Romina, Torrebadell, Montse, Vega-Garcia, Nerea, Rives, Susana, Mallo, Mar, Sole, Francesc, Mead, Adam J., Roberts, Irene, Thongjuea, Supat, Psaila, Bethan, Juan, Manel, Delgado, Julio, Urbano-Ispizúa, Alvaro, Ribera, Josep María, Orfao, Alberto, Roy, Anindita, Menendez, Pablo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Immunobiology and Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346957/
https://www.ncbi.nlm.nih.gov/pubmed/35421218
http://dx.doi.org/10.1182/blood.2021014840

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346957/
https://www.ncbi.nlm.nih.gov/pubmed/35421218
http://dx.doi.org/10.1182/blood.2021014840

Ejemplares similares